Preventive PIPAC for high-risk colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a preventive treatment called PIPAC for people with colorectal cancer that has a high risk of spreading to the lining of the abdomen. PIPAC delivers chemotherapy directly into the abdomen during a short procedure to try to stop the cancer from coming back there.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had surgery for colorectal cancer (colon, colorectal junction, or high rectum).
- Your cancer stage is pT4 pN0-2 cM0 pMMR, or pT3-4 pN0-2 cM0 with positive cytology, or pT3-4 pN0-2 M1c with limited spread to one area of the abdomen that was removed during surgery.
- You are in good daily health (able to do all your usual activities) with a performance status of 0 or 1.
- You are 18 to 80 years old.
- You have not had any chemotherapy or other cancer treatment before surgery.
- You do not have certain genetic forms of colorectal cancer (hereditary or dMMR/MSI-high).
- You do not have other distant cancer spread (except small lung spots that will be watched).
- You do not have inflammatory bowel disease, are not pregnant or breastfeeding, and have no allergy to oxaliplatin.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy, an immunotherapy drug (anti-PD-1 antibody), and sitagliptin before surgery for colorectal cancer that has not spread to other organs. The goal is to see if this approach can shrink the tumor and improve outcomes.
This Phase 1 trial tests PIPAC, a way to deliver anti-cancer medicine directly into the abdomen using a minimally invasive procedure. It is for people with peritoneal spread from certain cancers to see whether this approach is safe and potentially helpful.
This Phase 2 study tests whether spraying chemotherapy into the abdomen (through a small procedure) after colon cancer surgery can lower the chance the cancer comes back. It is meant for people with high-risk tumor features but who have had surgery and have no proven relapse yet.
This trial tests if a special type of chemotherapy delivered as a mist during surgery (PIPAC) can help prevent the spread of stomach cancer. It is for people with advanced but not yet metastatic stomach cancer who have not had prior treatment.
This study tests a new way to deliver chemotherapy directly into the abdomen (called PIPAC) for women with advanced ovarian cancer who cannot have surgery to remove all tumors. The goal is to see if this approach is safe and helps slow cancer growth.
This trial tests a new way to deliver chemotherapy directly into the abdomen (called PIPAC) for people with cancer spread to the lining of the belly. It uses the drug mitomycin and is for patients who cannot have standard surgery or heated chemotherapy.
Hear when a new Colorectal Cancer Control and Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.